Read our Recent Headlines


November 17 Biotech Update

We had a decent bounce yesterday and perhaps we will get a continuation. The sector is over sold as are a bunch of individual names. I am not convinced the.

Dave-Trading – December 2017

*** David Sobek is a disciplined value investor.  Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.***.

November 15 Biotech Update

The sector continues to struggle and at least today we can blame the larger macro market but the fact is if the markets in general are going to correct, the.

November 13 Biotech Update

Another week and another noticeable lack of M&A. At this point, we are so use to nothing happening that it seems like a normal week (which it is). Even though.

November 10 Biotech Update

We have our answer to what the sector wants to do as the number of large moves higher by the odd stock is over and the large days down continue..

November 8 Biotech Update

Today certainly has some interesting news for stocks I have talked about but unlikely to have an impact on the sector. In any case, it seems to be more of.

November 7 Biotech Update

Some news to start the day but nothing particularly thesis changing. The sector seemed to hold onto to some of its gains yesterday but more or less a treading water.

Introduction


Quick Facts

10

Analysts

500

Clients

22k

Followers

900

Reports

2.7k

Comments

5

Years

Overview

Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.


The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!